Role of Data Managers in AE Review in Clinical Trials

Published on 23/12/2025

The Critical Role of Data Managers in Reviewing Adverse Events

Table of Contents

Introduction: Why Data Managers Are Key to AE Review

In clinical trials, the accurate documentation and review of adverse events (AEs) is a cornerstone of patient safety and regulatory compliance. While investigators are responsible for recording AEs in electronic case report forms (eCRFs), data managers play a pivotal role in reviewing, cleaning, and reconciling this data to ensure its integrity. Regulatory authorities such as the FDA, EMA, and MHRA consistently emphasize the importance of clean, complete, and consistent AE data as part of safety monitoring and inspection readiness.

Data managers act as the bridge between clinical site documentation and sponsor pharmacovigilance systems. Their oversight ensures that AE information is not only captured but also validated, reconciled, and aligned with global reporting requirements. This article explores the role of data managers in AE review, their responsibilities, regulatory expectations, case studies, and best practices for inspection readiness.

Core Responsibilities of Data Managers in AE Review

Data managers’ responsibilities in AE review extend beyond data entry checks. Their role includes:

Completeness checks: Ensuring mandatory fields such as onset, resolution, severity, causality, and outcome are captured.
Consistency checks:

Validating that AE data aligns with related modules such as concomitant medications, dosing, and labs.

Query generation: Issuing queries for ambiguous, missing, or inconsistent AE documentation.

Reconciliation: Comparing AE entries in eCRFs with safety databases to ensure consistency.

Audit readiness: Maintaining clean AE datasets and documentation trails for regulatory inspections.

For example, if an investigator enters “Recovered” as an outcome but leaves the resolution date blank, data managers are responsible for generating queries to resolve the inconsistency before database lock.

Case Study: Missing Seriousness Criteria in SAE Documentation

In a Phase II cardiovascular trial, data managers identified multiple serious adverse events (SAEs) where the seriousness criteria field had not been completed. Without this information, the events were misclassified as routine AEs, delaying expedited reporting. Data managers raised queries to sites, obtained the missing data, and corrected the classification. This intervention prevented a potential regulatory finding during inspection and reinforced the critical role of data managers in safety data integrity.

Regulatory Expectations for Data Manager Oversight

Regulators view data managers as a critical part of the quality system for clinical data management. Expectations include:

FDA: Expects AE data in IND safety reports to reconcile with eCRFs and narratives.
EMA: Requires consistency between eCRF AE entries and EudraVigilance submissions.
MHRA: Audits data manager oversight processes to ensure completeness and audit trails.
ICH E6(R2): Highlights the role of data management in ensuring accurate and verifiable trial data.

Inspection findings often cite missing AE causality, delayed resolution updates, or discrepancies between eCRFs and safety databases. Data managers are expected to prevent these issues through proactive oversight. Databases like ClinicalTrials.gov emphasize the importance of accurate AE information in trial transparency, underscoring the need for robust review systems.

Challenges Faced by Data Managers in AE Review

AE review is complex and often hampered by challenges such as:

Incomplete entries: Missing seriousness, causality, or action taken fields.
Ambiguity: Vague free-text AE terms that hinder MedDRA coding.
Delayed updates: Ongoing AEs not updated at follow-up visits.
Discrepancies: Mismatches between AE eCRF data and safety databases.

These challenges require continuous vigilance by data managers, supported by SOPs, edit checks, and escalation pathways to ensure timely resolution.

Best Practices for Data Managers in AE Review

To ensure high-quality AE datasets, data managers should apply the following best practices:

Develop data management plans (DMPs) with AE-specific review procedures.
Use real-time edit checks in eCRFs to prevent incomplete data entry.
Reconcile AE data with pharmacovigilance systems at regular intervals.
Perform trend analysis to identify systemic issues across sites.
Maintain audit trails to demonstrate oversight during inspections.

For example, a sponsor may include in their DMP that all SAEs must be reconciled weekly between eCRFs and the safety database, with discrepancies escalated to the medical monitor.

Role in Database Lock and Trial Close-Out

Before database lock, data managers perform a final reconciliation of AE data. Tasks include:

Ensuring all AE queries are resolved.
Confirming consistency between CRFs, narratives, and safety databases.
Verifying ongoing AEs are updated with final status.

Failure to reconcile AE data before lock can delay trial close-out, regulatory submissions, and even lead to inspection findings. Thus, data managers are integral to ensuring that safety data are complete, consistent, and ready for submission.

Key Takeaways

Data managers are essential to the integrity of AE documentation in clinical trials. Their role ensures:

Completeness and consistency of AE fields in eCRFs.
Accurate reconciliation with pharmacovigilance systems.
Inspection readiness through robust audit trails and oversight.
Early identification of systemic issues through trend analysis.

By implementing these practices, data managers strengthen regulatory compliance, support accurate safety reporting, and ultimately protect patient safety across global clinical development programs.